Correlation of a predefined set of 96 inflammatory proteins between the serum and intestinal tissue within patients with inflammatory bowel disease

Inflammatory bowel disease (IBD) comprise two major entities of chronic intestinal disorders: Crohn¡¯s disease (CD) and ulcerative colitis (UC). The ongoing expansion in the therapeutic armamentarium for IBD has improved therapeutic outcome for many patients. However, both CD and UC are highly heterogenic conditions, both in clinical presentation and in response to therapy. It remains difficult to predict which patient is likely to respond to a particular treatment at any given stage of their disease. To optimize the use of currently available therapeutic interventions, a more personalized diagnostic and therapeutic care-path is needed. Currently it may take several years to find an effective treatment for an individual patient. Hence, from both a patient and a pharmaco-economic point of view, predictive biomarkers for therapy response would be of great benefit. Most studies that aimed to discover new IBD biomarkers on a protein level have mainly focused on plasma/serum. However, recent studies suggest that analysing material closer to or directly from the location of disease may yield higher concentrations of potential biomarkers. However, although the diseased intestine itself may contain increased protein concentrations and facilitate biomarker discovery, the use of this material in routine care is limited due to the invasive nature of the procedure. Therefore, matched validation of candidate markers in serum is required. We aim to investigate the correlation between the protein profiles of the serum and the gut mucosa.

Most studies that aimed to discover new IBD biomarkers on a protein level have mainly focused on plasma/serum. However, recent studies suggest that analysing material closer to or directly from the location of disease may yield higher concentrations of potential biomarkers. However, although the diseased intestine itself may contain increased protein concentrations and facilitate biomarker discovery, the use of this material in routine care is limited due to the invasive nature of the procedure. Therefore, matched validation of candidate markers in serum is required. We aim to investigate the correlation between the protein profiles of the serum and the gut mucosa.

Cross sectional

procurement of 5 intestinal biopsies

1 5mL serum tube withdrawal